-
May 10, 2022
F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update -
May 02, 2022
F-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022 -
Apr 08, 2022
F-star Therapeutics Presents a Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022 -
Mar 14, 2022
F-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update -
Mar 10, 2022
F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference -
Mar 02, 2022
F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022 -
Mar 01, 2022
F-star Therapeutics Appoints James Sandy as Chief Development Officer -
Jan 20, 2022
F-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3 -
Jan 07, 2022
F-star Therapeutics to Participate in Upcoming Investor Conferences -
Jan 05, 2022
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
Pagination
